Mikiko Kusano

Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021

H. Maeda, K. Tsukamoto, Marika Uchida, 2022, Clinical pharmacology and therapeutics.

Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study

T. Naoe, T. Miyamoto, S. Morita, 2018, Cancer science.

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

T. Naoe, S. Fujiwara, M. Kizaki, 2021, International Journal of Clinical Oncology.